A phase II study of oxaliplatin (O) and gemcitabine (G) first line chemotherapy in patients with advanced biliary tract cancers.

被引：0
|
作者：
Gebbia, N
Verderame, F
Di Leo, R
Santangelo, D
Cicero, G
Valerio, MR
Arcara, C
Badalamenti, G
Fulfaro, F
Carreca, I
机构：
[1] Dept Oncol, Palermo, Sicily, Italy
[2] Azienda Osp, Sciacca, Italy
[3] Dept Expt & Clin Onc, Palermo, Sicily, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：340S / 340S
页数：1
相关论文
共 50 条
  • [21] JASPAC 02: A phase II study of gemcitabine and oxaliplatin (GEMOX) for gemcitabine-refractory advanced biliary tract cancer
    Ohno, I.
    Fukutomi, A.
    Furuse, J.
    Okusaka, T.
    Asayama, M.
    Nakamori, S.
    Ishii, H.
    Okuno, T.
    Yamanaka, T.
    Boku, N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S631 - S632
  • [22] Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study
    Park, JS
    Oh, SY
    Kim, SH
    Kwon, HC
    Kim, JS
    Hyo, JK
    Kim, YH
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (02) : 68 - 73
  • [23] Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer
    Harder, J.
    Riecken, B.
    Kummer, O.
    Lohrmann, C.
    Otto, F.
    Usadel, H.
    Geissler, M.
    Opitz, O.
    Henss, H.
    BRITISH JOURNAL OF CANCER, 2006, 95 (07) : 848 - 852
  • [24] Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer
    J Harder
    B Riecken
    O Kummer
    C Lohrmann
    F Otto
    H Usadel
    M Geissler
    O Opitz
    H Henß
    British Journal of Cancer, 2006, 95 : 848 - 852
  • [25] Capecitabine (X) and oxaliplatin (O) combination chemotherapy in patients (pts) with advanced gall bladder or biliary tract cancer: A phase II study
    Evans, T. R. Jeffry
    Wylie, Eileen
    Garcia, Jorge Curto
    Coxon, Fareeda
    Wall, Lucy
    Eatock, Martin
    Maughan, Tim
    Highley, Martin
    Zimmerli, Priska Butzberger
    ANNALS OF ONCOLOGY, 2006, 17 : 320 - 320
  • [26] Randomized, multicenter phase II trial of CAP7.1 in patients with advanced biliary tract cancers.
    Pape, Ulrich-Frank
    Kasper, Stefan
    Sinn, Marianne
    Caca, Karel
    Kuhlmann, Jan
    Keilholz, Ulrich
    Vogel, Arndt
    Utku, Nalan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [27] Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
    Chen, Ruijia
    Zhang, Yalan
    Lin, Kongying
    Huang, Defu
    You, MaoJin
    Lai, Yanjin
    Wang, Jinye
    Hu, Yingying
    Li, Na
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [28] A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers
    Laura W. Goff
    Dana B. Cardin
    Jennifer G. Whisenant
    Liping Du
    Tatsuki Koyama
    Kimberly B. Dahlman
    Safia N. Salaria
    Ruth T. Young
    Kristen K. Ciombor
    Jill Gilbert
    Stephen James Smith
    Emily Chan
    Jordan Berlin
    Investigational New Drugs, 2017, 35 : 95 - 104
  • [29] A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers
    Goff, Laura W.
    Cardin, Dana B.
    Whisenant, Jennifer G.
    Du, Liping
    Koyama, Tatsuki
    Dahlman, Kimberly B.
    Salaria, Safia N.
    Young, Ruth T.
    Ciombor, Kristen K.
    Gilbert, Jill
    Smith, Stephen James
    Chan, Emily
    Berlin, Jordan
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (01) : 95 - 104
  • [30] A phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients (Pts) with advanced biliary tract cancers.
    Javle, Milind M.
    Bridgewater, John A.
    Gbolahan, Olumide B.
    Jungels, Christiane
    Cho, May Thet
    Papadopoulos, Kyriakos P.
    Thistlethwaite, Fiona C.
    Canon, Jean-Luc Re
    Cheng Lulu
    Ioannidis, Sonia
    Gogov, Sven
    Aung, Naing
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
12345